Introduction
The 2009 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium was held October 7-9, in San Francisco, California. The multidisciplinary symposium encouraged engaged participation and collaborative interaction. Educational lectures, discussions, and tumor boards were designed to help clinicians interpret the wealth of information available and translate findings into the larger clinical context. The information exchange highlighted emerging science and the future of breast cancer care.
Featured Content
• Incorporation of Translational Science Into Clinical Trials
• Supercharging Hormonal Therapy
• PARP Inhibitors in MBC
• End of the Anthracycline Era?
• Cardiovascular Health and Breast Cancer
• Bone Health and Breast Cancer
Editors
Terry P. Mamounas, MD, MPH, FACS, bio | Eric P. Winer, MD, bio
Media: Newsletter
Estimated time to complete activity: 1.5 hours |
Release date: November 20, 2009 | Expiration date: November 19, 2010
Statement of Need
As many advances have been realized in the treatment of breast cancer, challenges still exist. Therefore, the dissemination of critical research findings to the medical oncology community in a timely manner is critical for clinical trial enrollment and reporting, new treatment adaptation, and potential to impact the long-term outcomes of these patients. Continuing medical education programs are important vehicles to assist in the timely distribution and application of this key information in order to improve patient outcomes.
Target Audience
The target audience for the program includes medical, surgical, and radiation oncologists, as well as allied oncology healthcare professionals charged with the care of patients with breast cancer.
Learning Objectives
Upon completion of this educational program, participants should be better able to:
- Select appropriate adjuvant treatment regimens based on current understanding of clinical markers, efficacy, and safety profiles
- Explain the rationale behind novel agents and combinations to overcome resistance mechanisms in breast cancer
- Evaluate emerging new therapeutic options for treatment of metastatic breast cancer by reviewing ongoing and planned clinical trials
- Describe ongoing research regarding strategies of incorporating bisphosphonates into breast cancer treatment paradigms
|
ACCREDITATION INFORMATION
PHYSICIAN CONTINUING EDUCATION
ACCREDITATION STATEMENT
Educational Concepts Group, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Educational Concepts Group, LLC designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
| PHARMACIST CONTINUING EDUCATION |
 |
| Educational Concepts Group, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |
|
Type of Activity: Knowledge-based
Educational Concepts Group, LLC designates this continuing education activity for 1.5 contact hours (0.15 CEUs) (UAN 199-000-09-076-H01-P).
|
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CE credit for this activity.
During the period November 20, 2009 through November 19, 2010, participants must
1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-test and activity evaluation form.
CME/CE CREDIT
Physicians and pharmacists who complete the post-test with a score of 70% or better may view and print their credit letter or statement of credit via the website, www.educationalconcepts.net.
DISCLOSURE OF OFF-LABEL USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. ECG does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity do not necessarily represent the views of ECG. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
CME/CE INQUIRIES
For further information, please contact
Educational Concepts Group, LLC
1300 Parkwood Circle SE
Suite 325
Atlanta, Georgia 30339
Phone: 1.770.933.1681
Fax: 1.770.933.1692
www.educationalconcepts.net
ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by an educational grant from Genentech BioOncology.
|
FACULTY DISCLOSURE STATEMENT
All faculty participating in continuing education activities sponsored by ECG are expected to disclose to the audience any real or apparent commercial financial affiliations related to the content of their presentations/materials.
THE FOLLOWING FACULTY MEMBERS HAVE DECLARED RELEVANT FINANCIAL RELATIONSHIPS
Terry P. Mamounas, MD, MPH, FACS
Consultant Fees
Agendia, Genentech BioOncology, Genomic Health, Inc., GlaxoSmithKline, Novartis, Pfizer Inc, sanofi-aventis Group
Honorarium
Agendia, Genentech BioOncology, Genomic Health, Inc., GlaxoSmithKline, Novartis, Pfizer Inc, sanofi-aventis Group
Speakers’ Bureau
Genentech BioOncology, Genomic Health, Inc., sanofi-aventis Group
Eric P. Winer, MD
Grants/Research Support
Genentech BioOncology
ECG HAS DECLARED THE FOLLOWING FINANCIAL RELATIONSHIPS
ECG receives educational grants from pharmaceutical industry and other commercial sources. Planners, managers, and other staff members at ECG have no relevant financial relationships to disclose.
None of the contents may be reproduced in any form without prior written permission from the publisher. This activity may be accessed at www.educationalconcepts.net.
ACKNOWLEDGEMENT
The faculty wish to thank Maureen Haas, PharmD, BCPS, BCOP, a paid employee of ECG, for assistance in writing this document.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Please refer to the official prescribing information for each product or consult the Physicians’ Desk Reference for discussion of approved indications, contraindications, and warnings.
|
